SciSparc Ltd. Announces Acquisition of Neurothera Labs Inc.

SciSparc Ltd., a clinical-stage pharmaceutical company, has announced the closing of its acquisition of Neurothera Labs Inc., a publicly traded company on the TSX Venture Exchange (TSXV). The transaction involved the transfer of SciSparc's advanced clinical stage pharmaceutical portfolio and a 51% equity stake in SciSparc Nutraceuticals Inc. to Neurothera. The total enterprise value of Neurothera was approximately US$3.3 million, while the transferred assets were valued at approximately US$11.6 million. As part of the deal, SciSparc received 63,300,000 common shares of Neurothera, 4,000,000 common share purchase warrants, and up to 48,000,000 contingent rights. Following the transaction, SciSparc holds a controlling interest of approximately 75% in Neurothera, which could increase to 84% upon the fulfillment of certain milestones. The transaction also included a CAD 1,000,000 convertible note commitment from SciSparc to Neurothera. The common shares of Neurothera are expected to resume trading on the TSXV under the symbol 'NTLX' on or about October 24, 2025.